MRC1 and colorectal cancer: This is in sharp contrast with advanced colorectal cancer, where only about 5% of patients may benefit from ICI (MMR deficient or MSI-H) [19], reflecting an ‘immune-cold’ microenvironment in the majority of colorectal cancer.